Fate Therapeutics (FATE) Change in Receivables (2018 - 2026)
Fate Therapeutics (FATE) posted Change in Receivables of -$212000.0 for Q1 2026, down 190.99% on a QoQ basis from $233000.0 in Q4 2025, and up 81.31% year-over-year from -$116930.0 in Q1 2025.
Fate Therapeutics (FATE) Change in Receivables (2018 - 2026) Analysis & Trends
Fate Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at -$212000.0 for Q1 2026.
- Quarterly Change in Receivables rose 81.31% year-over-year to -$212000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (down 279.73% YoY) and the FY2025 annual result came in at -$2.6 million, down 335.76% from the prior year.
- Change in Receivables was -$212000.0 for Q1 2026 at Fate Therapeutics, down from $233000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $28.3 million in Q4 2022 and bottomed at -$25.0 million in Q1 2023.
- A 5-year average of -$504294.1 and a median of -$713000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 1970.11% — and 2023, when it plunged 1373.2%.
- Fate Therapeutics' Change in Receivables stood at $28.3 million in 2022, then sank by 98.98% to $288000.0 in 2023, then sank by 304.17% to -$588000.0 in 2024, then surged by 139.63% to $233000.0 in 2025, then tumbled by 190.99% to -$212000.0 in 2026.
- Business Quant data shows FATE's Change in Receivables at -$212000.0 in Q1 2026, $233000.0 in Q4 2025, and -$713000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | -212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | -713,000.00 |
| Sep 30, 2025 | -713,000.00 |
| Jun 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.01 Mn |
| Mar 31, 2025 | -1.13 Mn |
| Mar 31, 2025 | -1.13 Mn |
| Dec 31, 2024 | -588,000.00 |
| Dec 31, 2024 | -588,000.00 |
| Sep 30, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 190,000.00 |
| Mar 31, 2024 | -968,000.00 |
| Mar 31, 2024 | -968,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |